文章摘要
丁重阳,李天女,孙晋,黄庆娟,丁其勇.18F-FDG PET/CT在弥漫性大B细胞淋巴瘤临床分期及评价化疗反应的价值[J].南京医科大学学报,2014,(1):
18F-FDG PET/CT在弥漫性大B细胞淋巴瘤临床分期及评价化疗反应的价值
The value of 18F-FDG PET/CT for clinical staging and assessing therapeutic response to chemotherapy in patients with diffuse large B-cell lymphoma
投稿时间:2013-06-17  修订日期:2013-09-10
DOI:10.7655/NYDXBNS201401016
中文关键词: 淋巴瘤,大B细胞,弥漫性  药物疗法  正电子发射型计算机断层扫描  18氟-氟代脱氧葡萄糖  临床分期
英文关键词: Lymphoma, large B-cell, diffuse  Drug therapy  Positron emission tomography  Fluorine-18 fluoro-deoxy-glucose  Clinical staging
基金项目:
作者单位E-mail
丁重阳 南京医科大学第一附属医院核医学科 chongyangding@163.com 
李天女 南京医科大学第一附属医院核医学科 litiannv@126.com 
孙晋 南京医科大学第一附属医院核医学科  
黄庆娟 南京医科大学第一附属医院核医学科  
丁其勇 南京医科大学第一附属医院核医学科  
摘要点击次数: 982
全文下载次数: 1821
中文摘要:
      [摘要] 目的: 探讨18F-FDG PET/CT在弥漫性大B细胞淋巴瘤(diffuse B-cell large lymphoma,DLBCL)临床分期及评价化疗中期治疗反应的价值。方法:29例初诊的DLBCL化疗前和化疗中期均行18F-FDG PET/CT检查,根据肿瘤对化疗的反应将病例分为无反应组、部分反应组及完全反应组,比较三组患者的完全缓解率。应用SPSS17.0软件进行统计学分析,完全缓解率的比较采用χ2检验。结果 :18F-FDG PET/CT改变了10.3%(3/29)患者的临床分期。无反应组、部分反应组及完全反应组的临床完全缓解率分别为16.7%(1/6)、69.7% (9/13) 和80.0% (8/10),3组间差异有统计学意义(χ2=14.810,P=0.005)。完全反应组、部分反应组的完全缓解率明显高于无反应组(χ2=4.310,P=0.038;χ2=5.730,P=0.017)。结论 :18F-FDG PET/CT显像有助于临床分期;化疗中期18F-FDG PET/CT显像有助于预测化疗疗效。
英文摘要:
      [Abstract] Objective: To explore the value of 18F-FDG PET/CT on the clinical staging and assessment of chemotherapy response in patients with diffuse large B-cell lymphoma (DLBCL). Methods: 18F-FDG PET/CT was performed before and after 3 or 4 cycles of chemotherapy in 29 patients with DLBCL. The patients were divided into three groups: no response group, partial response group and complete response group. Compared the complete remission rate (CR)between the three groups. χ2 test was performed with SPSS 17.0. Results: The stage of disease was changed in three patients (10.3%, 3/29)on the basis of pre-treatment 18F-FDG PET/CT. CR rates of no response group, partial group and complete group were 16.7%, 69.7% and 80.0%, respectively(χ2=14.810,P=0.005). CR rates of the complete group and partial group were significantly higher than those of no response group (χ2=4.310,P=0.038;χ2=5.730,P=0.017). Conclusion: 18F-FDG PET/CT may be useful for clinical staging and assessment of chemotherapy response in DLBCL.
查看全文   查看/发表评论  下载PDF阅读器
关闭